Abstract: A pharmaceutical composition for treating tuberculotic diseases with no side effect/low side effect is provided by the present invention, which pharmaceutically effective amount of one or more compounds chosen from isoniazid, rifampin, pyrazinamide and ethambutol, and pharmaceutically effective amount of substances which can reduce the side effect of the antituberculosis agents.

Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

Abstract: The present invention features a novel, low side-effect pharmaceutical compound complex, comprising the pharmaceutically effective dose of isoniazid (INH) and pharmaceutically effective dose of one of the following compounds.

Abstract: The present invention features a novel, low side-effect pharmaceutical compound complex, comprising the pharmaceutically effective dose of isoniazid (INH) and pharmaceutically effective dose of one of the following compounds.

Abstract: This invention relates to novel imidazole derivatives of formula a ##STR1## and pharmaceutically acceptable salts of these compounds, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.7 and R.sup.8 are as disclosed herein. These compounds are protein kinase inhibitors useful in the treatment of atherosclerosis, psoriasis, alopecia, and tumors.

Abstract: The present invention provides N- and O-substituted aminophenol derivatives of the general formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, G and L are as hereinbefore defined. The present invention also provides intermediates for the preparation of these aminophenol derivatives of general formula (I), as well as the use of the aminophenol derivatives of general formula (I) for the determination of hydrolases, as well as for the preparation of agents for carrying out determinations of hydrolysis.

Abstract: The levorotatory isomer of benzhydrylsulfinylacetamide has useful pharmaceutical activity on the central nervous system, particularly as an antidepressant and stimulant in the treatment of hypersomnia and Alzheimer's disease.

Abstract: A halogen-free flameproofed thermoplastic molding material consists of a halogen-free thermoplastic resin (A) and one or more further halogen-free components.The thermoplastic resin (A) is present in an amount of from 30 to 90% by weight, based on the molding material. The latter contains, as further components, from 1 to 50% by weight of a phenol/aldehyde resin (B), from 1 to 50% by weight of a nitrogen-containing organic compound (C) and from 3 to 50% by weight of a phosphorus-containing organic compound (D), the percentages in each case being based on the molding material.The molding material is used for the production of flameproofed moldings.